









市場行情
/
股票
/
nasdaq-vrtx
/

Vertex Pharmaceuticals Inc

VRTX

447.380USD

-2.140-0.48%

收盤 12/18, 16:00（美東）報價延遲15分鐘

113.61B總市值

31.27本益比TTM



Vertex Pharmaceuticals Inc

447.380

-2.140-0.48%

概覽公司財務分析

概覽

公司

財務

分析

關於 Vertex Pharmaceuticals Inc 公司

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Vertex Pharmaceuticals Inc簡介



公司代碼VRTX

公司名稱Vertex Pharmaceuticals Inc

上市日期Jul 24, 1991

CEOKewalramani (Reshma)

員工數量6100

證券類型Ordinary Share

年結日Jul 24

公司地址50 Northern Avenue

城市BOSTON

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02210

電話16173416393

網址https://www.vrtx.com/

公司代碼VRTX

上市日期Jul 24, 1991

CEOKewalramani (Reshma)

Vertex Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

25.80K

-14.85%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

16.13K

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

15.31K

-2.22%

Mr. Lloyd A. Carney

Independent Director

6.32K

-11.24%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.57K

-5.51%

Ms. Jennifer J. Schneider

Independent Director

1.72K

+86.33%

名稱

名稱/職務

職務

持股

持股變動

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

25.80K

-14.85%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

16.13K

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

TRIKAFTA

2.55B

86.65%

Other product revenues

205.70M

6.99%

ALYFTREK

156.80M

5.33%

CASGEVY

30.40M

1.03%

地區USD

名稱

營收

佔比

United States

1.83B

62.08%

Europe

910.90M

30.94%

Other

205.60M

6.98%

業務

地區

業務USD

名稱

營收

佔比

TRIKAFTA

2.55B

86.65%

Other product revenues

205.70M

6.99%

ALYFTREK

156.80M

5.33%

CASGEVY

30.40M

1.03%

股東統計

更新時間: 11月15日週六

持股股東

股東類型

持股股東

佔比

Capital World Investors

10.21%

The Vanguard Group, Inc.

9.50%

Capital Research Global Investors

6.52%

BlackRock Institutional Trust Company, N.A.

5.70%

State Street Investment Management (US)

4.57%

其他

63.49%

持股股東

佔比

Capital World Investors

10.21%

The Vanguard Group, Inc.

9.50%

Capital Research Global Investors

6.52%

BlackRock Institutional Trust Company, N.A.

5.70%

State Street Investment Management (US)

4.57%

其他

63.49%

股東類型

持股股東

佔比

Investment Advisor

60.06%

Investment Advisor/Hedge Fund

28.01%

Research Firm

2.35%

Pension Fund

2.27%

Bank and Trust

2.08%

Sovereign Wealth Fund

1.50%

Hedge Fund

1.14%

Individual Investor

0.14%

Insurance Company

0.09%

其他

2.36%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

2933

249.27M

98.24%

-2.14M

2025Q2

2933

252.71M

98.56%

+2.47M

2025Q1

2977

252.24M

98.22%

-39.54K

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

2023Q2

2488

248.89M

96.55%

-7.11M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Capital World Investors

28.73M

11.21%

+198.84K

+0.70%

Jun 30, 2025

The Vanguard Group, Inc.

23.86M

9.31%

+479.23K

+2.05%

Jun 30, 2025

Capital Research Global Investors

16.11M

6.28%

+1.57M

+10.81%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

14.15M

5.52%

+156.31K

+1.12%

Jun 30, 2025

State Street Investment Management (US)

11.78M

4.59%

-13.43K

-0.11%

Jun 30, 2025

Geode Capital Management, L.L.C.

5.93M

2.31%

+166.99K

+2.90%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

5.26M

2.05%

-18.59K

-0.35%

Aug 31, 2025

Wellington Management Company, LLP

4.81M

1.88%

-641.36K

-11.76%

Jun 30, 2025

Capital International Investors

2.64M

1.03%

+1.99M

+305.59%

Jun 30, 2025

AllianceBernstein L.P.

4.38M

1.71%

+424.81K

+10.75%

Jun 30, 2025

持股ETF



更新時間: 12月5日週五

機構名稱

佔比

VanEck Biotech ETF

9.71%

ProShares Ultra Nasdaq Biotechnology

8.83%

Invesco Nasdaq Biotechnology ETF

8.76%

iShares Biotechnology ETF

7.43%

Invesco Biotechnology & Genome ETF

5.35%

Natixis Loomis Sayles Focused Growth ETF

4.48%

First Trust NASDAQ Pharmaceuticals ETF

4.23%

First Trust NYSE Arca Biotechnology Index Fund

3.5%

Franklin Genomic Advancements ETF

3.33%

Simplify Health Care ETF

3.25%

VanEck Biotech ETF

佔比9.71%

ProShares Ultra Nasdaq Biotechnology

佔比8.83%

Invesco Nasdaq Biotechnology ETF

佔比8.76%

iShares Biotechnology ETF

佔比7.43%

Invesco Biotechnology & Genome ETF

佔比5.35%

Natixis Loomis Sayles Focused Growth ETF

佔比4.48%

First Trust NASDAQ Pharmaceuticals ETF

佔比4.23%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.5%

Franklin Genomic Advancements ETF

佔比3.33%

Simplify Health Care ETF

佔比3.25%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Vertex Pharmaceuticals Inc的前五大股東是誰？



Vertex Pharmaceuticals Inc的前五大股東如下：
Capital World Investors
持有股份：28.73M
佔總股份比例：11.21%。
The Vanguard Group, Inc.
持有股份：23.86M
佔總股份比例：9.31%。
Capital Research Global Investors
持有股份：16.11M
佔總股份比例：6.28%。
BlackRock Institutional Trust Company, N.A.
持有股份：14.15M
佔總股份比例：5.52%。
State Street Investment Management (US)
持有股份：11.78M
佔總股份比例：4.59%。